PIPE-791
Idiopathic Pulmonary Fibrosis
Key Facts
About Contineum Therapeutics
Contineum Therapeutics is a public, clinical-stage biotech (NASDAQ: CTNM) with a mission to develop oral, small molecule drugs for neuroinflammatory and fibrotic diseases. Its strategy leverages human genetic validation of specific GPCR targets, most notably the M1 muscarinic and LPA1 receptors, to derisk development and address large patient populations. Key achievements include advancing its lead asset, PIPE-307, to Phase 2 in multiple sclerosis and depression, and progressing a second key asset, PIPE-791, through Phase 1 for idiopathic pulmonary fibrosis and progressive MS. The company operates with a lean, virtual structure, utilizing strategic partnerships and CROs to advance its pipeline efficiently.
View full company profileAbout Contineum Therapeutics
Contineum Therapeutics is a public, clinical-stage biotech (NASDAQ: CTNM) with a mission to develop oral, small molecule drugs for neuroinflammatory and fibrotic diseases. Its strategy leverages human genetic validation of specific GPCR targets, most notably the M1 muscarinic and LPA1 receptors, to derisk development and address large patient populations. Key achievements include advancing its lead asset, PIPE-307, to Phase 2 in multiple sclerosis and depression, and progressing a second key asset, PIPE-791, through Phase 1 for idiopathic pulmonary fibrosis and progressive MS. The company operates with a lean, virtual structure, utilizing strategic partnerships and CROs to advance its pipeline efficiently.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| BIO 300 | Humanetics Corp. | Research |
| Undisclosed | Biossil | Phase 2/3 |
| KITCL27 | Kither Biotech | Preclinical |
| BRS101 | BreStem Therapeutics | Phase 1 |
| T03 | Treamid Therapeutics | Phase 1 |
| ING-006 | Innosphera Pharma | Preclinical |
| MNM‑siRNA IPF | Interna TX | Preclinical |
| Pirfenidone | Gyre Therapeutics | Marketed |